A random walk in oncogene space: The quest for targets

Cell Growth and Differentiation

Volumn 10, Issue 12, 1999, Pages 777-784

  Vogt, Peter K ^a   Aoki, Masahiro ^a   Bottoli, Ivan ^a   Chang, Hwai Wen ^a,b   Fu, Shu Ling ^a   Hecht, Andreas ^a,c   Iacovoni, Jason S ^a   Jiang, Bing Hua ^a   Kruse, Ulrich ^a,d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Stratagene   (United States)

^c MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^d EVOTEC BioSystems AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; CHICKEN; GENE ACTIVATION; GENE CONTROL; GENE TARGETING; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BINDING SITES; CELL MEMBRANE; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FIBROBLASTS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYMPHOID ENHANCER-BINDING FACTOR 1; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

ANIMALIA; GALLUS GALLUS;

EID: 0033403192     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Pawson, T., and Hunter, T. Signal transduction and growth control in normal and cancer cells. Curr. Opin. Genet. Dev., 4: 1-4, 1994.
2. Hunter, T. Oncoprotein networks. Cell, 88: 333-346, 1997.
3. Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., and Vogt, P. K. Transformation of chicken cells by the gene encoding the catalytic subunit of Pl 3-kinase. Science (Washington DC), 276: 1848-1850, 1997.
4. Burgering, B. M., and Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (Lond.), 376: 599-602, 1995.
5. Kohn, A. D., Kovacina, K. S., and Roth, R. A. Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing Ser/Thr kinase. EMBO J., 14: 4288-4295, 1995.
6. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell, 81: 727-736, 1995.
7. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., and Hawkins, P. T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science (Washington DC), 279: 710-714, 1998.
8. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol., 7: 261-269, 1997.
9. Alessi, D. R., Deak, M., Casamayor, A., Caudwell, F. B., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., Ashworth, A., and Bownes, M. 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol., 7: 776-789, 1997.
10. Anderson, K. E., Coadwell, J., Stephens, L. R., and Hawkins, P. T. Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B. Curr. Biol., 8: 684-691, 1998.
11. Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., and Hemmings, B. A. Role of translocation in the activation and function of protein kinase B. J. Biol. Chem., 272: 31515-31524, 1997.
12. Bellacosa, A., Chan, T. O., Ahmed, N. N., Datta, K., Malstrom, S., Stokoe, D., McCormick, F., Feng, J., and Tsichlis, P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene, 17: 313-325, 1998.
13. Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P., and Vogt, P. K. The akt kinase: molecular determinants of oncogenicity. Proc. Natl. Acad. Sci. USA, 95: 14950-14955, 1998.
14. Boettiger, D. Interaction of oncogenes with differentiation programs. Curr. Top. Microbiol. Immunol., 747: 31-78, 1989.
15. Falcone, G., Tato, F., and Alema, S. Distinctive effects of the viral oncogenes myc, erb, fps, and src on the differentiation program of quail myogenic cells. Proc. Natl. Acad. Sci. USA, 82: 426-430, 1985.
16. Falcone, G., Alema, S., and Tato, F. Transcription of muscle-specific genes is repressed by reactivation of pp60v-src in postmitotic quail myotubes. Mol. Cell. Biol., 11: 3331-3338, 1991.
17. Grossi, M., Calconi, A., and Tato, F. v-jun oncogene prevents terminal differentiation and suppresses muscle-specific gene expression in ASV-17-infected muscle cells. Oncogene, 6: 1767-1773, 1991.
18. Holtzer, H., Biehl, J., Yeoh, G., Meganathan, R., and Kaji, A. Effect of oncogenic virus on muscle differentiation. Proc. Natl. Acad. Sci. USA, 72: 4051-4055, 1975.
19. Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., and Clevers, H. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/-colon carcinoma. Science (Washington DC), 275: 1784-1787, 1997.
20. Lassar, A. B., Thayer, M. J., Overell, R. W., and Weintraub, H. Transformation by activated ras or fos prevents myogenesis by inhibiting expression of MyoD1. Cell, 58: 659-667, 1989.
21. Miner, J. H., and Wold, B. J. c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation. Mol. Cell. Biol., 11: 2842-2851, 1991.
22. Su, H. Y., Bos, T. J., Monteclaro, F. S., and Vogt, P. K. Jun inhibits myogenic differentiation. Oncogene, 6: 1759-1766, 1991.
23. Jiang, B. H., Zheng, J. Z., and Vogt, P. K. An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. Proc. Natl. Acad. Sci. USA, 95: 14179-14183, 1998.
24. Jiang, B. H., Aoki, M., Zheng, J. Z., Li, J., and Vogt, P. K. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc. Natl. Acad. Sci. USA, 96: 2077-2081, 1999.
25. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (Lond.), 378: 785-789, 1995.
26. Cross, D. A., Watt, P. W., Shaw, M., van der Kaay, J., Downes, C. P., Holder, J. C., and Cohen, P. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett., 406: 211-215, 1997.
27. Shaw, M., Cohen, P., and Alessi, D. R. Further evidence that the inhibition of glycogen synthase kinase-3β by IGF-1 is mediated by PDK1/ PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett., 416: 307-311, 1997.
28. Aberle, H., Schwartz, H., and Kemler, R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell. Biochem., 61: 514-523, 1996.
29. Bullions, L C., and Levine, A. J. The role of β-catenin in cell adhesion, signal transduction, and cancer. Curr. Opin. Oncol., 10: 81-87, 1998.
30. Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3 β. Curr. Biol., 8: 573-581, 1998.
31. Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., and Kikuchi, A. Axin. A negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. EMBO J., 17: 1371-1384, 1998.
32. Jou, T. S., Stewart, D. B., Stappert, J., Nelson, W. J., and Marrs, J. A. Genetic and biochemical dissection of protein linkages in the cadherin-catenin complex. Proc. Natl. Acad. Sci. USA, 92: 5067-5071, 1995.
33. Kishida, S., Yamamoto, H., Ikeda, S., Kishida, M., Sakamoto, I., Koyama, S., and Kikuchi, A. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of β-catenin. J. Biol. Chem., 273: 10823-10826, 1998.
34. Nakamura, T., Hamada, F., Ishidate, T., Anai, K., Kawahara, K., Toyoshima, K., and Akiyama, T. Axin, an inhibitor of the Wnt signalling pathway, interacts with β-catenin, GSK-3β and APC and reduces the β-catenin level. Genes Cells, 3: 395-403, 1998.
35. Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 76: 3797-3804, 1997.
36. Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. Functional interaction of β-catenin with the transcription factor LEF-1. Nature (Lond.), 382: 638-642, 1996.
37. Riese, J., Yu, X., Munnerlyn, A., Eresh, S., Hsu, S. C., Grosschedl, R., and Bienz, M. LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. Cell, 88: 777-787, 1997.
38. Porfiri, E., Rubinfeld, B., Albert, I., Hovanes, K., Waterman, M., and Polakis, P. Induction of a β-catenin-LEF-1 complex by wnt-1 and transforming mutants of β-catenin. Oncogene, 75: 2833-2839, 1997.
39. Huber, O., Korn, R., McLaughlin, J., Ohsugi, M., Herrmann, B. G., and Kemler, R. Nuclear localization of β-catenin by interaction with transcription factor LEF-1. Mech. Dev., 59: 3-10, 1996.
40. Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science (Washington DC), 275: 1790-1792, 1997.
41. Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science (Washington DC), 275: 1787-1790, 1997.
42. Miyoshi, Y., Nagase, H., Ando, H., Horii, A., Ichii, S., Nakatsuru, S., Aoki, T., Miki, Y., Mori, T., and Nakamura, Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet., 1: 229-233, 1992.
43. Aoki, M., Hecht, A., Kruse, U., Kemler, R., and Vogt, P. K. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc. Natl. Acad. Sci. USA, 96: 139-144, 1999.
44. Maki, Y., Bos, T. J., Davis, C., Starbuck, M., and Vogt, P. K. Avian sarcoma virus 17 carries the jun oncogene. Proc. Natl. Acad. Sci. USA, 84: 2848-2852, 1987.
45. Vogt, P. K. Oncogenic transformation by Jun. In: P. E. Angel and P. A. Herrlich (eds.), The Fos and Jun Families of Transcription Factors, pp. 203-219. Boca Raton, FL: CRC Press, 1994.
46. Karin, M., Liu, Z., and Zandi, E. AP-1 function and regulation. Curr. Opin. Cell. Biol., 9: 240-246, 1997.
47. Kouzarides, T., and Ziff, E. Leucine zippers of fos, jun and GCN4 dictate dimerization specificity and thereby control DNA binding. Nature (Lond.), 340: 568-571, 1989.
48. Suzuki, T., Murakami, M., Onai, N., Fukuda, E., Hashimoto, Y., Sonobe, M. H., Kameda, T., Ichinose, M., Miki, K., and Iba, H. Analysis of AP-1 function in cellular transformation pathways. J. Virol., 68: 3527-3535, 1994.
49. Benbrook, D. M., and Jones, N. C. Heterodimer formation between CREB and JUN proteins. Oncogene, 5: 295-302, 1990.
50. Morgan, I. M., Asano, M., Havarstein, L S., Ishikawa, H., Hiiragi, T., Ito, Y., and Vogt, P. K. Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication. Oncogene, 8: 1135-1140, 1993.
51. Morgan, I. M., Havarstein, L. S., Wong, W. Y., Luu, P., and Vogt, P. K. Efficient induction of fibrosarcomas by v-jun requires mutations in the DNA binding region and the transactivation domain. Oncogene, 9: 2793-2797, 1994.
52. May, G. H., Funk, M., Black, E. J., Clark, W., Hussain, S., Woodgett, J. R., and Gillespie, D. A. An oncogenic mutation uncouples the v-Jun oncoprotein from positive regulation by the SAPK/JNK pathway in vivo. Curr. Biol., 8: 117-120, 1998.
53. Havarstein, L. S., Morgan, I. M., Wong, W. Y., and Vogt, P. K. Mutations in the Jun delta region suggest an inverse correlation between transformation and transcriptional activation. Proc. Natl. Acad. Sci. USA, 89: 618-622, 1992.
54. Hartl, M., and Vogt, P. K. Oncogenic transformation by Jun: role of transactivation and homodimerization. Cell Growth Differ., 3: 899-908, 1992.
55. Oliviero, S., Robinson, G. S., Struhl, K., and Spiegelman, B. M. Yeast GCN4 as a probe for oncogenesis by AP-1 transcription factors: transcriptional activation through AP-1 sites is not sufficient for cellular transformation. Genes Dev., 6: 1799-1809, 1992.
56. Hussain, S., Kilbey, A., and Gillespie, D. A. v-Jun represses c-jun proto-oncogene expression in vivo through a 12-O-tetradecanoylphorbol-13-acetate-responsive element in the proximal gene promoter. Cell Growth Differ., 9: 677-686, 1998.
57. Gao, M., Morgan, I., and Vogt, P. K. Differential and antagonistic effects of v-Jun and c-Jun. Cancer Res., 56: 4229-4235, 1996.
58. Kilbey, A., Black, E. J., Unlu, M., and Gillespie, D. A. The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction. Oncogene, 12: 2409-2418, 1996.
59. Usui, H., Falk, J. D., Dopazo, A., de Lecea, L., Erlander, M. G., and Sutcliffe, J. G. Isolation of clones of rat striatum-specific mRNAs by directional tag PCR subtraction. J. Neurosci., 14: 4915-4926, 1994.
60. Goller, M. E., Iacovoni, J. S., Vogt, P. K., and Kruse, U. Glutaredoxin is a direct target of oncogenic jun. Oncogene, 76: 2945-2948, 1998.
61. Fu, S., Bottoli, I., Goller, M., and Vogt, P. K. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc. Natl. Acad. Sci. USA, 96: 5716-5721, 1999.
62. Kruse, U., Iacovoni, J. S., Goller, M. E., and Vogt, P. K. Hormone-regulatable neoplastic transformation induced by a Jun-estrogen receptor chimera. Proc. Natl. Acad. Sci. USA, 94: 12396-12400, 1997.
63. Naef, M., Yokoyama, M., Friess, H., Buchler, M. W., and Korc, M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int. J. Cancer, 66: 315-321, 1996.
64. Kobrin, M. S., Funatomi, H., Friess, H., Buchler, M. W., Stathis, P., and Korc, M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem. Biophys. Res. Commun., 202: 1705-1709, 1994.
65. Mishima, K., Higashiyama, S., Asai, A., Yamaoka, K., Nagashima, Y., Taniguchi, N., Kitanaka, C., Kirino, T., and Kuchino, Y. Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol., 96: 322-328, 1998.